<DOC>
	<DOCNO>NCT00004419</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine efficacy toxic effect recombinant human insulin-like growth factor I ( rhIGF-I ) carbohydrate tolerance , insulin action , insulin secretion , hyperandrogenism , hyperlipidemia patient severe insulin resistance fail therapy . II . Determine dose time response rhIGF-I carbohydrate homeostasis secondary abnormality patient population . III . Determine effect rhIGF-I insulin clearance , regulation insulin-like growth factor bind protein 1 , regulation sex hormone bind globulin , hypothalamic pituitary gonadal axis patient population .</brief_summary>
	<brief_title>Study Recombinant Human Insulin-Like Growth Factor I Patients With Severe Insulin Resistance</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This open label study . Patients receive first dose subcutaneous recombinant human insulin-like growth factor I ( rhIGF-I ) day 7 . Patients receive rhIGF-I twice daily 15-30 minute breakfast dinner , hospitalize first week therapy . Patients return outpatient exam day 19 rhIGF-I therapy . Approximately 30 day therapy , patient readmitted clinical center repeat screen test . Patients receive maintenance therapy rhIGF-I 6-12 month . A washout period follow maintenance therapy phase . Patients follow weekly , biweekly , monthly depend blood glucose response patient rhIGF-I therapy . Weekly phone contact study coordinator mandatory time . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Hyperglycemia</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Complement Factor I</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Hematologically proven severe insulin resistance without diabetes Fasting insulin great 40 U/mL Post glucose insulin great 300 U/mL ( unless overt diabetes mellitus present ) Prior/Concurrent Therapy Endocrine therapy : No concurrent oral hypoglycemic agent and/or insulin Other : No concurrent birth control pills Patient Characteristics Not pregnant Negative pregnancy test Effective barrier contraceptive method must use fertile patient Good health</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>endocrine disorder</keyword>
	<keyword>insulin resistance</keyword>
	<keyword>rare disease</keyword>
</DOC>